Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026

Billionaire investor Stanley Druckenmiller's Duquesne Family Office has strategically reallocated its portfolio, liquidating positions in high-performing AI stocks like Nvidia and Palantir due to valuation concerns. Concurrently, Duquesne has made a significant investment in Teva Pharmaceuticals, acquiring nearly 16 million shares valued over $267 million by Q2 2025. This pivot underscores a focus on Teva's growth strategy, its robust late-stage drug pipeline including three Phase 3 candidates for major ailments, and an attractive valuation at less than 8 times forward earnings, a sentiment reinforced by positive analyst outlooks and raised revenue estimates.

Analysis

Stanley Druckenmiller's Duquesne Family Office strategically reallocated its portfolio in Q2 2024, liquidating positions in high-performing AI stocks Nvidia (NVDA) and Palantir (PLTR). This divestment, despite NVDA and PLTR generating 36% and 142% year-to-date gains respectively, was driven by valuation concerns, with Druckenmiller noting NVDA's "rich" valuation as its market cap entered the trillions.

Concurrently, Duquesne made a significant investment in Teva Pharmaceuticals (TEVA), acquiring nearly 16 million shares valued over $267 million by the end of Q2 2025. This pivot highlights Teva's "pivot-to-growth" strategy and its robust late-stage drug pipeline, which includes three Phase 3 candidates targeting major ailments like asthma, inflammatory bowel disease, and schizophrenia. New drug applications are planned for submission starting late this year through 2029.

Druckenmiller likely finds Teva's valuation attractive, trading at less than 8 times forward earnings, which is considered undemanding given its growth prospects. This positive outlook is reinforced by UBS analyst Ashwani Verma, who maintained a buy rating, raised Teva's 2030 revenue estimate to $6.6 billion, and anticipates less Medicare discount pressure on key drugs like Austedo.

Key Decisions for Investors

• Evaluate portfolio exposure to high-valuation AI stocks like NVDA and PLTR, considering potential profit-taking or rebalancing strategies as exemplified by Druckenmiller's move.
• Research Teva Pharmaceuticals (TEVA) as a potential value play, focusing on its late-stage pipeline, "pivot-to-growth" strategy, and current valuation multiple below 8x forward earnings.
• Monitor upcoming new drug application submissions for Teva from late 2024 through 2029, as these regulatory milestones could significantly impact future revenue and stock performance.